Publication: Autoantibodies in cancer: a systematic review of their clinical role in the most prevalent cancers
| dc.contributor.author | Montero-Calle, Ana Maria | |
| dc.contributor.author | Garranzo-Asensio, Maria | |
| dc.contributor.author | Moreno-Casbas, Teresa | |
| dc.contributor.author | Campuzano, Susana | |
| dc.contributor.author | Barderas Manchado, Rodrigo | |
| dc.contributor.funder | Instituto de Salud Carlos III | |
| dc.contributor.funder | Agencia Estatal de Investigación (España) | |
| dc.contributor.funder | Unión Europea. Fondo Europeo de Desarrollo Regional (FEDER/ERDF) | |
| dc.contributor.funder | Unión Europea. European Innovation Council (EIC) | |
| dc.date.accessioned | 2024-10-14T10:14:02Z | |
| dc.date.available | 2024-10-14T10:14:02Z | |
| dc.date.issued | 2024 | |
| dc.description.abstract | Although blood autoantibodies were initially associated with autoimmune diseases, multiple evidence have been accumulated showing their presence in many types of cancer. This has opened their use in clinics, since cancer autoantibodies might be useful for early detection, prognosis, and monitoring of cancer patients. In this review, we discuss the different techniques available for their discovery and validation. Additionally, we discuss here in detail those autoantibody panels verified in at least two different reports that should be more likely to be specific of each of the four most incident cancers. We also report the recent developed kits for breast and lung cancer detection mostly based on autoantibodies and the identification of novel therapeutic targets because of the screening of the cancer humoral immune response. Finally, we discuss unsolved issues that still need to be addressed for the implementation of cancer autoantibodies in clinical routine for cancer diagnosis, prognosis, and/or monitoring. | |
| dc.description.peerreviewed | Sí | |
| dc.description.sponsorship | The author(s) declare financial support was received for the research, authorship, and/or publication of this article. This work was supported by the financial support of the PI20CIII/00019 and PI23CIII/00027 grants from the AES-ISCIII program to RB. The financial support of Grants PID2022-136351OB-I00 to SC and PID2022-140307OB-I00 to RB funded by MCIN/AEI/10.13039/501100011033 and by “ERDF A way of making Europe” are also gratefully acknowledged. The financial support provided by the European Innovation Council (EIC) through the EIC Pathfinder Open 2023 project (Grant No. 101130574) to RB is also acknowledged. | |
| dc.format.page | 1455602 | |
| dc.format.volume | 15 | |
| dc.identifier.citation | Front Immunol. 2024 Aug 21:15:1455602. | |
| dc.identifier.doi | 10.3389/fimmu.2024.1455602 | |
| dc.identifier.e-issn | 1664-3224 | |
| dc.identifier.journal | Frontiers in immunology | |
| dc.identifier.pubmedID | 39234247 | |
| dc.identifier.uri | https://hdl.handle.net/20.500.12105/25096 | |
| dc.language.iso | eng | |
| dc.publisher | Frontiers Media | |
| dc.relation.projectID | info:eu-repo/grantAgreement/EC/101130574 | |
| dc.relation.projectID | info:eu-repo/grantAgreement/ES/PI20CIII/00019 | |
| dc.relation.projectID | info:eu-repo/grantAgreement/ES/PI23CIII/00027 | |
| dc.relation.projectID | info:eu-repo/grantAgreement/ES/PID2022-136351OB-I00 | |
| dc.relation.projectID | info:eu-repo/grantAgreement/ES/PID2022-140307OB-I00 | |
| dc.relation.publisherversion | https://doi.org/10.3389/fimmu.2024.1455602 | |
| dc.repisalud.centro | ISCIII::Unidad Funcional de Investigación de Enfermedades Crónicas (UFIEC) | |
| dc.repisalud.centro | ISCIII::Unidad de Investigación en Cuidados de Salud (Investén-ISCIII) | |
| dc.repisalud.institucion | ISCIII | |
| dc.rights.accessRights | open access | |
| dc.rights.license | Attribution 4.0 International | |
| dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ | |
| dc.subject | Autoantibodies | |
| dc.subject | Breast cancer | |
| dc.subject | Cancer autoantibodies | |
| dc.subject | Colorectal cancer | |
| dc.subject | Humoral immune response | |
| dc.subject | Lung cancer | |
| dc.subject | Prostate cancer | |
| dc.subject | Proteomics | |
| dc.subject.mesh | Animals | |
| dc.subject.mesh | Autoantibodies | |
| dc.subject.mesh | Biomarkers, Tumor | |
| dc.subject.mesh | Early Detection of Cancer | |
| dc.subject.mesh | Humans | |
| dc.subject.mesh | Neoplasms | |
| dc.subject.mesh | Prognosis | |
| dc.title | Autoantibodies in cancer: a systematic review of their clinical role in the most prevalent cancers | |
| dc.type | review article | |
| dc.type.hasVersion | VoR | |
| dspace.entity.type | Publication | |
| relation.isAuthorOfPublication | 3e80abe1-6578-487f-8201-f4c5ed3a674c | |
| relation.isAuthorOfPublication | 840089f4-4c1e-4ac0-8214-93464312af82 | |
| relation.isAuthorOfPublication | f7f2cba2-57c8-4041-ad68-be66ae4c22f8 | |
| relation.isAuthorOfPublication | dfb1f4f9-c8e8-4087-9db5-6477d4f154e4 | |
| relation.isAuthorOfPublication.latestForDiscovery | 3e80abe1-6578-487f-8201-f4c5ed3a674c |
Files
Original bundle
1 - 1 of 1
Loading...
- Name:
- AutoantibodiesCancerSystematicReview_2024.pdf
- Size:
- 4.67 MB
- Format:
- Adobe Portable Document Format


